SUMMARY

• RYBREVANT (amivantamab-vmjw) is a low fucose, fully human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
• A real-world study retrospectively evaluated the use of RYBREVANT with or without osimertinib and with or without concurrent radiation therapy in patients with EGFR-mutated (EGFRm) NSCLC (N=61).²
  • Of all patients, 37 (58.7%) received concomitant osimertinib and 25 (39.1%) received concomitant radiation.
  • Of the evaluated patients who received concomitant osimertinib, 1 had a complete response (CR), 12 had a partial response (PR), 4 had stable disease (SD), 15 had progressive disease (PD), and 3 had responses that were not applicable (NA).
  • Among the 37 patients who received concomitant osimertinib and were evaluated for safety, the adverse events (AEs) documented were infusion reactions, rash, thrombocytopenia, and transaminitis (mostly grade 1-2) in addition to grade 1-2 paronychia, fatigue, edema, scalp ulcer, mucositis, nausea, and diarrhea, as well as grade 3 pneumonitis. No additional toxicities were noted except those expected with EGFR/MET inhibition.
• OSTARA (NCT05801029) is an ongoing, phase 2, single-arm, multicenter study evaluating the efficacy and safety of first-line osimertinib in combination with RYBREVANT in adult patients with locally advanced, metastatic, or recurrent non-squamous EGFRm (Exon 19 deletion or L858R) NSCLC. The primary endpoints are safety and investigator-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.³ Efficacy and safety results have not yet been published.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 24 October 2024.